JP2016512517A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016512517A5 JP2016512517A5 JP2016501158A JP2016501158A JP2016512517A5 JP 2016512517 A5 JP2016512517 A5 JP 2016512517A5 JP 2016501158 A JP2016501158 A JP 2016501158A JP 2016501158 A JP2016501158 A JP 2016501158A JP 2016512517 A5 JP2016512517 A5 JP 2016512517A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutical composition
- disease
- administered
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 28
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 239000007787 solid Substances 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000007565 gingivitis Diseases 0.000 claims 2
- 235000019359 magnesium stearate Nutrition 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 229920000609 methyl cellulose Polymers 0.000 claims 2
- 239000001923 methylcellulose Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 1
- 239000005711 Benzoic acid Substances 0.000 claims 1
- 201000005488 Capillary Leak Syndrome Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 206010014824 Endotoxic shock Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010061459 Gastrointestinal ulcer Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 claims 1
- 102000004157 Hydrolases Human genes 0.000 claims 1
- 108090000604 Hydrolases Proteins 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 208000004852 Lung Injury Diseases 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- VOMWKCDHHTZTHV-UIOOFZCWSA-N O1C(=NC=C1)C1=CC=C(OC2=CC=C(CCN3[C@@H]4CN([C@H](C3)C4)CC4=CC=C(C(=O)O)C=C4)C=C2)C=C1 Chemical compound O1C(=NC=C1)C1=CC=C(OC2=CC=C(CCN3[C@@H]4CN([C@H](C3)C4)CC4=CC=C(C(=O)O)C=C4)C=C2)C=C1 VOMWKCDHHTZTHV-UIOOFZCWSA-N 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000005141 Otitis Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010049771 Shock haemorrhagic Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 208000031932 Systemic capillary leak syndrome Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010069363 Traumatic lung injury Diseases 0.000 claims 1
- 206010044541 Traumatic shock Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000038016 acute inflammation Diseases 0.000 claims 1
- 230000006022 acute inflammation Effects 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 208000002029 allergic contact dermatitis Diseases 0.000 claims 1
- 208000030961 allergic reaction Diseases 0.000 claims 1
- 230000001668 ameliorated effect Effects 0.000 claims 1
- 208000003455 anaphylaxis Diseases 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 235000010233 benzoic acid Nutrition 0.000 claims 1
- 229940125388 beta agonist Drugs 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 229940124630 bronchodilator Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 229960005168 croscarmellose Drugs 0.000 claims 1
- 229960000913 crospovidone Drugs 0.000 claims 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 201000003146 cystitis Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000019258 ear infection Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 239000003172 expectorant agent Substances 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 208000001875 irritant dermatitis Diseases 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 231100000515 lung injury Toxicity 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 229940066491 mucolytics Drugs 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 235000012239 silicon dioxide Nutrition 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 210000003802 sputum Anatomy 0.000 claims 1
- 208000024794 sputum Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 229940037128 systemic glucocorticoids Drugs 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361776981P | 2013-03-12 | 2013-03-12 | |
| US61/776,981 | 2013-03-12 | ||
| PCT/US2014/023138 WO2014164658A1 (en) | 2013-03-12 | 2014-03-11 | Methods of inhibiting leukotriene a4 hydrolase |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016512517A JP2016512517A (ja) | 2016-04-28 |
| JP2016512517A5 true JP2016512517A5 (enExample) | 2017-04-13 |
| JP6527851B2 JP6527851B2 (ja) | 2019-06-05 |
Family
ID=51658933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501158A Active JP6527851B2 (ja) | 2013-03-12 | 2014-03-11 | ロイコトリエンａ４加水分解酵素を阻害する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US9820974B2 (enExample) |
| EP (1) | EP2968359B1 (enExample) |
| JP (1) | JP6527851B2 (enExample) |
| AU (1) | AU2014249168B2 (enExample) |
| CA (1) | CA2905340C (enExample) |
| ES (1) | ES2864862T3 (enExample) |
| RU (1) | RU2686101C2 (enExample) |
| WO (1) | WO2014164658A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3205644A1 (en) | 2005-12-29 | 2017-08-16 | Celtaxsys Inc. | Diamine derivatives as inhibitors of leukotriene a4 hydrolase |
| WO2014164658A1 (en) * | 2013-03-12 | 2014-10-09 | Celtaxsys, Inc. | Methods of inhibiting leukotriene a4 hydrolase |
| CA2906084A1 (en) | 2013-03-14 | 2014-09-25 | Celtaxsys, Inc. | Inhibitors of leukotriene a4 hydrolase |
| EP2968264A4 (en) | 2013-03-14 | 2016-11-02 | Celtaxsys Inc | INHIBITORS OF LEUCOTRIENE A4 HYDROLASE |
| CA2906086A1 (en) | 2013-03-14 | 2014-09-25 | Celtaxsys, Inc. | Inhibitors of leukotriene a4 hydrolase |
| SG11202010115RA (en) * | 2018-05-15 | 2020-11-27 | Alkahest Inc | Treatment of aging-associated disease with modulators of leukotriene a4 hydrolase |
| ES3014615T3 (en) * | 2018-05-31 | 2025-04-23 | Celltaxis Llc | Method of reducing pulmonary exacerbations in respiratory disease patients |
| AU2020207638B2 (en) | 2019-01-11 | 2023-04-13 | Novartis Ag | LTA4H inhibitors for the treatment of Hidradenitis Suppurativa |
| TW202122078A (zh) | 2019-09-06 | 2021-06-16 | 瑞士商諾華公司 | 使用lta4h抑制劑治療肝臟疾病之方法 |
| EP4196478A1 (en) | 2020-08-14 | 2023-06-21 | Novartis AG | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof |
| AU2022376563A1 (en) | 2021-11-01 | 2023-12-07 | Alkahest, Inc. | Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases |
| CA3239752A1 (en) * | 2021-12-09 | 2023-06-15 | Stanley Glenn Rockson | Methods of treating lymphedema |
| WO2024254377A2 (en) * | 2023-06-09 | 2024-12-12 | Celltaxis, Llc | Methods of treating lipedema and lymphatic disease of the subcutaneous tissue |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL6815872A (enExample) | 1967-11-22 | 1969-05-27 | ||
| JPS5614663B2 (enExample) | 1971-08-21 | 1981-04-06 | ||
| US4582833A (en) | 1984-04-16 | 1986-04-15 | American Cyanamid Company | 2-(substituted-1-piperazinyl)[1,2,4]triazolo[1,5-a]pyrimidines |
| US4576943A (en) | 1984-10-09 | 1986-03-18 | American Cyanamid Company | Pyrazolo[1,5-a]pyrimidines |
| US5308852A (en) | 1992-06-29 | 1994-05-03 | Merck Frosst Canada, Inc. | Heteroarylnaphthalenes as inhibitors of leukotriene biosynthesis |
| US6506876B1 (en) | 1994-10-11 | 2003-01-14 | G.D. Searle & Co. | LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use |
| WO1997029774A1 (en) | 1996-02-13 | 1997-08-21 | G.D. Searle & Co. | Combinations, having immunosuppressive effects, containing a cyclooxygenase-2 inhibitor and a leukotriene a4 hydrolase inhibitor |
| US5952349A (en) | 1996-07-10 | 1999-09-14 | Schering Corporation | Muscarinic antagonists for treating memory loss |
| JP2000516611A (ja) | 1996-08-14 | 2000-12-12 | ワーナー―ランバート・コンパニー | Ｍｃｐ―１アンタゴニストとしての２―フェニルベンズイミダゾール誘導体 |
| US6309561B1 (en) | 1997-12-24 | 2001-10-30 | 3M Innovative Properties Company | Liquid crystal compounds having a chiral fluorinated terminal portion |
| US6380203B1 (en) | 1998-01-14 | 2002-04-30 | Merck & Co., Inc. | Angiogenesis inhibitors |
| GB9815880D0 (en) | 1998-07-21 | 1998-09-16 | Pfizer Ltd | Heterocycles |
| GB9919776D0 (en) | 1998-08-31 | 1999-10-27 | Zeneca Ltd | Compoujnds |
| AR023659A1 (es) | 1998-09-18 | 2002-09-04 | Vertex Pharma | Un compuesto inhibidor de p38, una composicion farmaceutica que lo comprende y el uso de dicha composicion en el tratamiento y prevencion de estados patologicos |
| US6699873B1 (en) | 1999-08-04 | 2004-03-02 | Millennium Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
| US6924313B1 (en) | 1999-09-23 | 2005-08-02 | Pfizer Inc. | Substituted tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity |
| WO2001056990A2 (en) | 2000-02-03 | 2001-08-09 | Eli Lilly And Company | Pyridine derivates as potentiators of glutamate receptors |
| US6451798B2 (en) | 2000-02-22 | 2002-09-17 | Cv Therapeutics, Inc. | Substituted alkyl piperazine derivatives |
| US6552023B2 (en) | 2000-02-22 | 2003-04-22 | Cv Therapeutics, Inc. | Aralkyl substituted piperazine compounds |
| JP2001354657A (ja) | 2000-06-09 | 2001-12-25 | Sds Biotech:Kk | 置換ピペラジン誘導体及び農園芸用殺菌剤 |
| DE60114518T2 (de) | 2000-07-06 | 2006-08-10 | Fuji Photo Film Co. Ltd., Minamiashigara | Flüssigkristallzusammensetzung, die Flüssigkristallmoleküle und Ausrichtungsmittel enthält |
| WO2002064211A1 (en) | 2001-02-09 | 2002-08-22 | Merck & Co., Inc. | Thrombin inhibitors |
| US7012075B2 (en) | 2001-03-02 | 2006-03-14 | Merck & Co., Inc. | Cathepsin cysteine protease inhibitors |
| AUPR362001A0 (en) | 2001-03-08 | 2001-04-05 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
| FR2826011B1 (fr) | 2001-06-14 | 2004-12-10 | Oreal | Nouveaux derives de la 7-oxo-dhea et utilisation cosmetique |
| SE0102616D0 (sv) | 2001-07-25 | 2001-07-25 | Astrazeneca Ab | Novel compounds |
| AU2002336532C1 (en) | 2001-09-14 | 2008-10-16 | Amgen, Inc | Linked biaryl compounds |
| WO2003037271A2 (en) | 2001-10-30 | 2003-05-08 | Millennium Pharmaceuticals,Inc. | Compounds, pharmaceutical compositions and methods of use therefor |
| AU2003270291A1 (en) | 2002-10-04 | 2004-04-23 | Ucb | 4-aminopiperidine derivatives, processes for their preparation and their use as medicaments |
| AU2003290527A1 (en) | 2002-10-17 | 2004-05-04 | Decode Genetics Ehf. | Susceptibility gene for myocardial infarction |
| WO2005027886A2 (en) | 2003-09-17 | 2005-03-31 | Decode Genetics Ehf. | Methods of preventing or treating recurrence of myocardial infarction |
| US7851486B2 (en) | 2002-10-17 | 2010-12-14 | Decode Genetics Ehf. | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment |
| AU2003300360A1 (en) | 2002-12-20 | 2004-07-22 | Migenix Corp. | Ligands of adenine nucleotide translocase (ant) and compositions and methods related thereto |
| CA2521000A1 (en) | 2003-04-03 | 2004-10-21 | Kyowa Hakko Kogyo Co., Ltd. | Preventive and/or therapeutic agent for neuropathic pain |
| WO2004099164A1 (en) | 2003-05-02 | 2004-11-18 | Rigel Pharmaceuticals, Inc. | Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating hcv infection |
| JP2005008581A (ja) | 2003-06-20 | 2005-01-13 | Kissei Pharmaceut Co Ltd | 新規なピラゾロ［１，５−ａ］ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途 |
| KR20060054408A (ko) | 2003-07-28 | 2006-05-22 | 얀센 파마슈티카 엔.브이. | 벤즈이미다졸, 벤즈티아졸 및 벤즈옥사졸 유도체 및ｌｔａ4 ｈ 조정자로서의 그의 용도 |
| EP1669348A4 (en) | 2003-09-30 | 2009-03-11 | Eisai R&D Man Co Ltd | NEW ANTIPILIC AGENT CONTAINING A HETEROCYCLIC COMPOUND |
| GB0326632D0 (en) * | 2003-11-14 | 2003-12-17 | Jagotec Ag | Dry powder formulations |
| DE10356579A1 (de) | 2003-12-04 | 2005-07-07 | Merck Patent Gmbh | Aminderivate |
| SE0303480D0 (sv) | 2003-12-19 | 2003-12-19 | Biovitrum Ab | Benzofuranes |
| EP1699847B1 (en) * | 2003-12-30 | 2011-04-13 | 3M Innovative Properties Company | Method for the preparation of medicinal compositions |
| ATE437880T1 (de) | 2004-02-04 | 2009-08-15 | Neurosearch As | Dimere azacyclische verbindungen und deren verwendung |
| WO2006033795A2 (en) | 2004-09-17 | 2006-03-30 | Wyeth | Substituted pyrazolo [1, 5-a] pyrimidines for inhibiting abnormal cell growth |
| CA2595791C (en) * | 2005-03-16 | 2013-10-08 | Meda Pharma Gmbh & Co. Kg | The combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases |
| KR20080003385A (ko) | 2005-03-31 | 2008-01-07 | 얀센 파마슈티카 엔.브이. | 페닐 및 피리딜 ｌｔａ４ｈ 조절제 |
| GB0514018D0 (en) | 2005-07-07 | 2005-08-17 | Ionix Pharmaceuticals Ltd | Chemical compounds |
| JP5133889B2 (ja) | 2005-09-21 | 2013-01-30 | デコード ジェネティクス イーエイチエフ | 炎症治療のためのビアリール基置換複素環ｌｔａ４ｈ阻害剤 |
| CN1947717B (zh) | 2005-10-14 | 2012-09-26 | 卓敏 | 选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用 |
| DE102005049954A1 (de) | 2005-10-19 | 2007-05-31 | Sanofi-Aventis Deutschland Gmbh | Triazolopyridin-derivate als Inhibitoren von Lipasen und Phospholipasen |
| EP3205644A1 (en) * | 2005-12-29 | 2017-08-16 | Celtaxsys Inc. | Diamine derivatives as inhibitors of leukotriene a4 hydrolase |
| AU2007215247B2 (en) | 2006-02-10 | 2012-12-13 | Transtech Pharma, Llc | Benzazole derivatives, compositions, and methods of use as Aurora kinase inhibitors |
| WO2008016131A1 (en) | 2006-08-04 | 2008-02-07 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
| CN101528709B (zh) | 2006-10-19 | 2012-02-01 | 弗·哈夫曼-拉罗切有限公司 | 对痕量胺相关受体有亲和性的氨基甲基-2-咪唑类 |
| US7893257B2 (en) | 2006-12-14 | 2011-02-22 | Janssen Pharmaceutica Nv | Process for the preparation of piperazinyl and diazepanyl benzamide derivatives |
| FR2911139A1 (fr) | 2007-01-05 | 2008-07-11 | Sanofi Aventis Sa | Nouveaux derives de phenyl-(4-phenyl-pyrimidin-2-yl)amines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk |
| FR2911140B1 (fr) | 2007-01-05 | 2009-02-20 | Sanofi Aventis Sa | Nouveaux derives de 2-anilino 4-heteroaryle pyrimides, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk |
| FR2911138B1 (fr) | 2007-01-05 | 2009-02-20 | Sanofi Aventis Sa | Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk |
| CN101687844B (zh) | 2007-07-02 | 2013-11-13 | 弗·哈夫曼-拉罗切有限公司 | 用作ccr2受体拮抗剂的咪唑衍生物 |
| AR068498A1 (es) * | 2007-09-27 | 2009-11-18 | Merck & Co Inc | Compuestos de oxadiazol para inhibicion de biosintesis de leucotrienos |
| AU2008334444B2 (en) | 2007-12-12 | 2011-12-15 | Astrazeneca Ab | Peptidyl nitriles and use thereof as dipeptidyl peptidase I inhibitors |
| BRPI0908529A2 (pt) | 2008-02-26 | 2015-09-29 | Novartis Ag | composto orgânicos |
| FR2928070A1 (fr) | 2008-02-27 | 2009-09-04 | Sumitomo Chemical Co | Composition agricole, utilisation d'un compose pour sa production et procede pour matriser ou prevenir les maladies des plantes. |
| US20100029657A1 (en) | 2008-02-29 | 2010-02-04 | Wyeth | Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof |
| KR101228378B1 (ko) | 2008-04-11 | 2013-01-31 | 얀센 파마슈티카 엔.브이. | 류코트리엔 α4 하이드롤레이즈의 조정제로서의 티아졸로피리딘-2-일옥시-페닐 및 티아졸로피라진-2-일옥시-페닐 아민 |
| EP2110374A1 (en) | 2008-04-18 | 2009-10-21 | Merck Sante | Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators |
| WO2010011912A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Trpv4 antagonists |
| GB2465897B (en) * | 2008-08-07 | 2011-02-09 | Argenta Discovery Ltd | Respiratory disease treatment |
| RU2011145278A (ru) * | 2009-04-09 | 2013-05-20 | Алкермес Фарма Айэленд Лимитед | Композиции клозапина с контролируемым высвобождением |
| CN102030700B (zh) | 2009-09-30 | 2016-06-01 | 中国医学科学院药物研究所 | 苯甲酰胺基羧酸类化合物及其制法和药物用途 |
| CN102741226B (zh) | 2009-10-30 | 2016-01-06 | 詹森药业有限公司 | 4-取代的-2-苯氧基-苯胺δ阿片类受体调节剂 |
| AU2010328419A1 (en) | 2009-12-07 | 2012-06-21 | Targacept, Inc. | 3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetylcholine receptor ligands |
| ES2823350T3 (es) | 2010-07-29 | 2021-05-06 | Rigel Pharmaceuticals Inc | Compuestos heterocíclicos que activan AMPK y métodos de uso de los mismos |
| WO2012067822A1 (en) | 2010-11-16 | 2012-05-24 | Abbott Laboratories | Pyrazolo [1, 5 -a] pyrimidin potassium channel modulators |
| TR201802550T4 (tr) | 2011-03-14 | 2018-03-21 | Boehringer Ingelheim Int | Lökotrien üretiminin benzodioksan inhibitörleri. |
| SG193424A1 (en) | 2011-03-15 | 2013-10-30 | Rib X Pharmaceuticals Inc | Antimicrobial agents |
| US9642888B2 (en) * | 2011-04-12 | 2017-05-09 | Moerae Matrix, Inc. | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
| ES2557450T3 (es) | 2011-05-23 | 2016-01-26 | Janssen Pharmaceutica, N.V. | Derivados de ácido picolinamido-propanoico útiles como antagonistas de los receptores de glucagón |
| CN103159742B (zh) | 2011-12-16 | 2015-08-12 | 北京韩美药品有限公司 | 5-氯嘧啶类化合物及其作为egfr酪氨酸激酶抑制剂的应用 |
| US9006235B2 (en) | 2012-03-06 | 2015-04-14 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| EP2827849A4 (en) | 2012-03-23 | 2015-11-18 | Univ Leland Stanford Junior | TREATMENT OF PULMONARY HYPERTONIA WITH LEUKOTRIENHEMMERN |
| WO2014164658A1 (en) * | 2013-03-12 | 2014-10-09 | Celtaxsys, Inc. | Methods of inhibiting leukotriene a4 hydrolase |
| CA2906084A1 (en) | 2013-03-14 | 2014-09-25 | Celtaxsys, Inc. | Inhibitors of leukotriene a4 hydrolase |
| CA2906086A1 (en) | 2013-03-14 | 2014-09-25 | Celtaxsys, Inc. | Inhibitors of leukotriene a4 hydrolase |
| EP2968264A4 (en) | 2013-03-14 | 2016-11-02 | Celtaxsys Inc | INHIBITORS OF LEUCOTRIENE A4 HYDROLASE |
-
2014
- 2014-03-11 WO PCT/US2014/023138 patent/WO2014164658A1/en not_active Ceased
- 2014-03-11 AU AU2014249168A patent/AU2014249168B2/en active Active
- 2014-03-11 EP EP14779776.5A patent/EP2968359B1/en active Active
- 2014-03-11 JP JP2016501158A patent/JP6527851B2/ja active Active
- 2014-03-11 CA CA2905340A patent/CA2905340C/en active Active
- 2014-03-11 RU RU2015137978A patent/RU2686101C2/ru active
- 2014-03-11 ES ES14779776T patent/ES2864862T3/es active Active
-
2015
- 2015-09-10 US US14/850,061 patent/US9820974B2/en active Active
-
2017
- 2017-11-02 US US15/801,482 patent/US10350197B2/en active Active
-
2019
- 2019-06-17 US US16/443,338 patent/US10898471B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016512517A5 (enExample) | ||
| JP6527851B2 (ja) | ロイコトリエンａ４加水分解酵素を阻害する方法 | |
| JP6111202B2 (ja) | 免疫抑制製剤 | |
| JP2017528507A5 (enExample) | ||
| JP2014532638A5 (enExample) | ||
| JP2018534348A5 (enExample) | ||
| JP2015145426A5 (enExample) | ||
| JP2016516808A5 (enExample) | ||
| JP2017222722A5 (enExample) | ||
| JP2024153665A (ja) | Ｐ２ｘ３調節剤としての置換イミダゾピリジン化合物の結晶形態およびそれらの使用 | |
| TW201417811A (zh) | 脂質異常症治療劑 | |
| JP2005522449A (ja) | Ｐｄｅ４阻害剤として有用なニコチンアミド誘導体 | |
| JP2015510916A5 (enExample) | ||
| JP5362151B2 (ja) | Ｐｇｄ２拮抗剤及びヒスタミン拮抗剤からなるアレルギー性鼻炎治療用医薬 | |
| JP4012935B2 (ja) | Ｐｄｅ４阻害剤として有用なニコチンアミド誘導体 | |
| JP2020510027A5 (enExample) | ||
| JP2013516475A5 (enExample) | ||
| FI4426307T3 (fi) | Uusi suun kautta otettava farmaseuttinen koostumus ja annosteluohjelma progressiivisen interstitiaalisen keuhkosairauden hoitoon | |
| JP2015189677A (ja) | ソリフェナシン非晶質体を含有する医薬組成物 | |
| JP2013177351A (ja) | Ｐｇｄ２拮抗剤及びロイコトリエン拮抗剤からなる喘息治療剤 | |
| EP3397285A1 (en) | Tablet formulations of montelukast sodium and rupatadine fumarate | |
| WO2011152808A1 (en) | Formulation comprising cefpodoxime proxetil and clavulanic acid | |
| CA3108713A1 (en) | Methods of administering therapy | |
| EP2575811A1 (en) | Pharmaceutical formulation comprising cefpodoxime proxetil and clavulanic acid | |
| JP2007008815A (ja) | Ｎ−（ベンゾイル）アミノ酸誘導体を有効成分とする呼吸器疾患治療剤 |